Opioid use disorder — CCFP MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Offer buprenorphine-naloxone or methadone with take-home naloxone
Explanation lettering: E = shown as B · B = shown as E
B is correct. Opioid agonist treatment with buprenorphine-naloxone or methadone reduces opioid-related morbidity and mortality; overdose prevention, including naloxone, should accompany treatment. C creates a high-risk treatment barrier. D is not evidence-based opioid-use-disorder treatment. E delays care without improving safety. A can precipitate severe withdrawal in someone currently dependent on opioids. Induction, dosing and pharmacy support should be individualized, including a low-dose initiation strategy if clinically indicated.
Reference: CMAJ: Management of opioid use disorder—2024 update to the national clinical practice guideline: https://www.cmaj.ca/content/196/38/E1280